콜로라도의 버킷 림프종 임상 시험
버킷 림프종 관련 연구 13개가 콜로라도 내 여러 지역에서 참여자를 모집하고 있습니다.
콜로라도의 도시
공식 연구 텍스트(영어)
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Children's Hospital Colorado, Aurora
피험자 모집 중1상
0세 ~ 18세 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT06173518A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Colorado, Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
피험자 모집 중2상
1세 ~ 30세 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT04546399Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora
피험자 모집 중1/2상
6 Months – 25 Years · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT06395103Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
피험자 모집 중관찰 연구
0세 ~ 38세 · 모든 성별 · 2026. 10. 29. 업데이트됨 · NCT06131801Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Hospital Colorado, Aurora
피험자 모집 중2상
365 Days · 모든 성별 · 2026. 10. 27. 업데이트됨 · NCT06317662A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Colorado, Aurora
피험자 모집 중2상
366 Days – 46 Years · 모든 성별 · 2026. 10. 27. 업데이트됨 · NCT06124157Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Colorado Blood Cancer Institute, Denver
피험자 모집 중1/2상
13세 ~ 90세 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT06533579Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- CBCI, Colorado Blood Cancer Institute, Denver
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 14. 업데이트됨 · NCT07648264UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
- Children's Hospital Colorado, Aurora
피험자 모집 중1/2상
31 Days – 30 Years · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT04544592Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospital Colorado, Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
피험자 모집 중3상
365 Days – 25 Years · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Colorado Children's Hospital, Denver
피험자 모집 중2상
7세 ~ 25세 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT05082519CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
- Children's Hospital Colorado, Aurora
피험자 모집 중1상
3 Months – 30 Years · 모든 성별 · 2025. 11. 28. 업데이트됨 · NCT06559189The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Children's Hospital Colorado, Aurora
피험자 모집 중2상
1세 ~ 25세 · 모든 성별 · 2025. 5. 4. 업데이트됨 · NCT03509961ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.